Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSB-5710 is a preclinical **topical live biotherapeutic product** being developed by Matrysis for **Solar Keratosis**. It is part of the company's skin microbiome bacteriotherapy platform, which uses beneficial skin-derived bacteria applied topically to rebalance the cutaneous microbiome and restore local microbial homeostasis. No discrete molecular target has been publicly disclosed for MSB-5710; its intended therapeutic mechanism appears to be microbiome modulation rather than direct engagement of a conventional drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSB-5710.